



Trabajo Original

Obesidad y síndrome metabólico

Dietary intervention with 2 different fat profiles; role of the rs822393 variant in metabolic parameter changes

Intervención dietética con 2 perfiles diferentes de grasa; papel de la variante rs822393 en la modificación de parámetros metabólicos

Rocío Aller¹, David Primo Martín^{1,2}, Olata Izaola^{1,2}, José Alfredo Martínez^{1,3}, Daniel de Luis Román^{1,2}

¹Centro de Investigación de Endocrinología y Nutrición Clínica de Valladolid (IENVA). Facultad de Medicina. Universidad de Valladolid. Valladolid, Spain. ²Servicio de Endocrinología y Nutrición Clínica de Valladolid. Hospital Clínico Universitario de Valladolid. Valladolid, Spain. ³IMBDEA Madrid. Spain

Abstract

Introduction: rs822393 is related to dietary intervention responses. The aim of our study was to analyze the metabolic effects of 2 hypocaloric diets with a different fat profile during 3 months according to the genetic variant rs822393.

Methods: a population of 361 obese patients were randomly allocated to one of two diets; Diet P (enriched in polyunsaturated fatty acids) vs. Diet M (enriched in monounsaturated fatty acids). Adiposity and biochemical parameters were determined. rs822393 was assessed by real-time PCR, with a dominant model analysis (CC vs CT+TT).

Results: genotype distribution was: 221 CC (61.2 %), 115 CT (31.9 %) and 25 TT (6.9 %). Basal and post-intervention HDL cholesterol, adiponectin levels and adiponectin/leptin ratio were lower in T-allele than non-T-allele carriers. After both diets, BMI, weight, fat mass, waist circumference, systolic blood pressure, insulin levels, HOMA-IR, leptin, total cholesterol and LDL-cholesterol improved significantly in both genotype groups. After Diet P, HDL-cholesterol (delta: 5.6 ± 1.1 mg/dl vs. 2.7 ± 0.9 mg/dl; $p = 0.01$), serum adiponectin (20.1 ± 2.9 ng/dl vs. 6.8 ± 3.0 ng/dl; $p = 0.02$) and adiponectin/leptin ratio (0.57 ± 0.1 units vs. 0.20 ± 0.08 units; $p = 0.03$) improved in non-T allele carriers. The same improvements were observed after Diet M: HDL-cholesterol (delta: 5.5 ± 0.8 mg/dl vs. 3.1 ± 0.9 mg/dl; $p = 0.03$), serum adiponectin (19.5 ± 2.9 ng/dl vs. 4.5 ± 2.8 ng/dl; $p = 0.01$), and adiponectin/leptin ratio (0.54 ± 0.1 units vs. 0.15 ± 0.08 units; $p = 0.03$). These parameters remained unchanged in T-allele carriers.

Conclusion: after two different hypocaloric diets, obese subjects with the T allele of rs822393 did not improve their adiponectin levels, ratio adiponectin/leptin, and HDL-cholesterol, despite loss of weight.

Keywords:

Hypocaloric diet. Dietary fat profile. rs822393.

Received: 25/04/2022 • Accepted: 12/11/2022

Statement of ethics: all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee, and with the 1964 Helsinki declaration and later amendments or comparable ethical standards. The study was approved by our local committee (Hospital Clínico Universitario de Valladolid Committee, P19/2017). A written informed consent was obtained from all participants included in the study.

Data availability statement: all data generated or analyzed during this study are included in this article. Further enquiries can be directed to the corresponding author.

Conflicts of interest: the authors declare none.

Aller R, Primo Martín D, Izaola O, Martínez JA, de Luis Román D. Dietary intervention with 2 different fat profiles; role of the rs822393 variant in metabolic parameter changes. *Nutr Hosp* 2023;40(1):49-58

DOI: <http://dx.doi.org/10.20960/nh.04205>

Correspondence:

Daniel de Luis Román. Instituto de Endocrinología y Nutrición. Facultad de Medicina. Universidad de Valladolid. C/ Los Perales, 16. Simancas 47130, Valladolid, Spain
e-mail: dadluis@yahoo.es

Resumen

Introducción: el polimorfismo rs822393 está relacionado con las respuestas a las intervenciones dietéticas. El objetivo de nuestro estudio fue analizar los efectos metabólicos de 2 dietas hipocalóricas con diferente perfil graso durante 3 meses según la variante genética rs822393.

Métodos: una muestra de 361 pacientes obesos se asignó aleatoriamente a una de dos dietas: dieta P (enriquecida en ácidos grasos poliinsaturados) y dieta M (enriquecida en ácidos grasos monoinsaturados). Se determinaron parámetros de adiposidad y bioquímicos; rs822393 se evaluó mediante PCR en tiempo real, con un análisis de modelo dominante (CC frente a CT+TT).

Resultados: la distribución del genotipo fue: 221 CC (61,2 %), 115 CT (31,9 %) y 25 TT (6,9 %). El colesterol HDL basal y posterior a la intervención, los niveles de adiponectina y la relación adiponectina/leptina fueron más bajos en los portadores del alelo T que en los no portadores del alelo T. Tras la intervención con ambas dietas, el IMC, el peso, la masa grasa, la circunferencia de la cintura, la presión arterial sistólica, los niveles de insulina, el HOMA-IR, la leptina, el colesterol total y el colesterol LDL mejoraron significativamente en ambos grupos de genotipo. Después de la dieta P: HDL-colesterol (delta: $5,6 \pm 1,1$ mg/dl vs. $2,7 \pm 0,9$ mg/dl; $p = 0,01$), adiponectina sérica ($20,1 \pm 2,9$ ng/dl vs. $6,8 \pm 3,0$ ng/dl; $p = 0,02$) y la relación adiponectina/leptina ($0,57 \pm 0,1$ unidades frente a $0,20 \pm 0,08$ unidades; $p = 0,03$) mejoraron en los no portadores del alelo T. Se observaron los mismos resultados después de la dieta M: HDL-colesterol (delta: $5,5 \pm 0,8$ mg/dl frente a $3,1 \pm 0,9$ mg/dl; $p = 0,03$), adiponectina sérica ($19,5 \pm 2,9$ ng/dl frente a $4,5 \pm 2,8$ ng/dl; $p = 0,01$) y relación adiponectina/leptina ($0,54 \pm 0,1$ unidades vs. $0,15 \pm 0,08$ unidades; $p = 0,03$). Estos parámetros permanecieron sin cambios en los portadores del alelo T.

Conclusión: tras las dos dietas hipocalóricas diferentes, los sujetos obesos con el alelo T de rs822393 no mejoraron los niveles de adiponectina, ratio adiponectina/leptina y colesterol HDL, a pesar de la pérdida de peso.

Palabras clave:

Dieta hipocalórica. Perfil de grasa en la dieta. rs822393.

INTRODUCTION

Obesity is a worldwide health problem of epidemic proportions that is related to diabetes *mellitus* type 2, hypertension, dyslipidemia, myocardial infarction, stroke, and cancer (1). Insulin resistance is also related to this whole set of complications associated with obesity. Moreover, some studies have reported that saturated fat worsens, whereas polyunsaturated and monounsaturated fats improve, insulin resistance (2).

In this context, adiponectin as expressed in adipose tissue is an important insulin sensitizer that regulates glucose metabolism and energy homeostasis (3,4). Adiponectin levels are decreased in obese patients (5), and hypo adiponectinemia is related to insulin resistance, diabetes *mellitus* type 2, and metabolic syndrome (6,7). Adiponectin is the most abundant adipokine, and is involved in the following functions: it enhances energy consumption and fatty acid oxidation, improves overall insulin sensitivity, and also has anti-inflammatory and anti-oxidant properties, as well as cardiovascular protective actions (8,9). Circulating concentrations have a strong genetic component, with heritability estimated at over 40 % (10). This adipokine is encoded by the *ADIPOQ* gene, which is located on chromosome 3 at q27 and has three exons (11). Interestingly, obese subjects show varying responses to dietary interventions, which suggests that a significant gene-dietary interaction occurs (12). Only a scarce number of all known *ADIPOQ* genetic variants have been evaluated regarding their effects in relation with biochemical changes after hypocaloric dietary interventions. One common genetic variant of the *ADIPOQ* gene is rs822393 (-4522C/T), which is located in the proximal promoter region. The single nucleotide polymorphism (SNP) rs822393 modulates adiponectin promoter activity and produces decreased circulating levels of adiponectin and worse insulin action (13,14). A short-term interventional study with a Mediterranean hypocaloric diet (15) showed increases adiponectin levels, adiponectin/leptin ratio, and HDL-cholesterol in non-T-allele carriers. This diet had a moderate caloric restriction of 500 calories for 3 months with a contribution of monounsaturated fats that accounted for 50 % of the caloric contribution from total fat amount. Finally, some SNPs of the *ADIPOQ* gene

have been demonstrated to interact with dietary intake of fat, and this interaction modifies adiponectin levels (16).

The aim of our study was to analyze the metabolic effects of two hypocaloric diet with different dietary fat profiles during 3 months according to the genetic variant rs822393 of *ADIPOQ*.

SUBJECTS AND METHODS

SUBJECTS AND CLINICAL INVESTIGATION

We performed a randomized interventional study. The Local Institutional Ethics Committee (HCUVA Committee P19/2017) approved the study protocol, and a written informed consent was obtained from participants, including genetic analyses. A continuous consecutive methodology was used to recruit 381 Caucasian obese patients taken care of at a tertiary Hospital in an urban area of Spain. Eligibility criteria were the following: obese patients with body mass index (BMI) ≥ 30 kg/m² and an age over 20 years. On the other hand, exclusion criteria included: evidence of previous cardiovascular or cerebrovascular disease, severe renal or hepatic disorders, active alcohol consumption (> 20 g/day), uncontrolled hypothyroidism, diabetes *mellitus*, receiving drugs known to influence lipid levels (fibrates, statins, hormonal therapy, glucocorticoids and anti-inflammatory drugs) or glucose levels (sulfonylureas, thiazolidinedione, insulin, glucagon-like peptide (GLP-1) receptor antagonists, S-GLT2 (type-2 sodium-glucose cotransporter), DPP-IV (dipeptidyl peptidase-4) inhibitors, metformin). Figure 1 shows a flow chart with the 381 recruited patients and 20 excluded patients; a total of 361 patients finished the study.

The parameters of the sample were registered at the beginning and after 3 months of dietary intervention. Adiposity parameters (weight, body mass index (BMI), total fat mass, and waist circumference) were recorded. Blood samples for analysis were drawn after a minimum of 10-h overnight fast, and serum was stored at -80 °C until analyzed. The next biochemical parameters were measured: total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, C-reactive protein (CRP), fasting glucose,

insulin, leptin, total adiponectin, and resistin. The following parameters were calculated: LDL-cholesterol, insulin resistance as homeostasis model assessment (HOMA-IR), and adiponectin/leptin ratio.

DIETARY INTERVENTION

All obese patients in this interventional study received individualized counseling on diet and exercise. As above-mentioned, patients were randomly allocated to one of two diets for a period of 12 weeks - Diet P (enriched in polyunsaturated fatty acids) and Diet M (enriched in monounsaturated fatty acids), and subtracting 500 daily calories from usual intake. The target percentage of energy derived from carbohydrate, fat and protein in the two diets were: Diet P (45.7 % of carbohydrates, 34.4 % of lipids and 19.9 % of proteins); Diet M (46.6 % of carbohydrates, 34.1 % of lipids and 19.2 % of proteins). The recommended distribution of dietary fats in Diet P was: 21.8 % of saturated fats, 55.5 % of monounsaturated fats and 22.7 % of polyunsaturated fats (7 g per day of w-6 fatty acids, 2 g per day of w-3 fatty acids, and a w6/w3 ratio of 3.5). The recommended distribution of fats in Diet M was: 21.7 % of saturated fats, 67.5 % of monounsaturated fats and 10.8 % of polyunsaturated fats. The recommended physical activity consisted of aerobic exercise at least three times per week (60 min each) such as running, walking, cycling or swimming. All recruited patients received instructions to record their daily dietary intake for five non-consecutive days. A dietitian assessed adherence to the diet every fourteen days with a phone call. Dietary records were analysed using a specific software (Dietosource[®], Genève, Switzerland), including national food composition tables as reference (17). Physical activity was recorded by each subject with a self-reported questionnaire.

GENOTYPING *ADIPOQ* GENE

Buffy coats removed from blood samples were stored in EDTA-coated tubes at -80 °C. Genomic DNA was extracted from 200 µL buffy coat using a standard salting out method by QIAamp[®] DNA blood kit. Oligonucleotide primers and probes were designed with the Beacon Designer 5.0 (Premier Biosoft International[®], LA, CA, USA). A 60 µL PCR reaction mixture containing 2 µL of genomic DNA, 10 µL of 10 x buffer reaction (My Taq[™] DNA polymerase, BIOLINE), 1.5 µL each of forward and reverse primers, 0.5 µL of My Taq DNA polymerase (My Taq[™] DNA polymerase, BIOLINE) and 44.5 µL of water were used in the reaction. PCR reaction was carried out using primer forward: 5'-ACGTTGGATGAAAGCATGACACGGAGCTTC-3' and reverse 5'-ACGTTGGATGAACCCCTACCCATGTCAGC-3' in a 2 µL final volume (Termociclador Life Technologies, LA, CA, USA). DNA was denatured at 90 °C for 3 min and subsequently by 50 cycles of denaturation at 90 °C for 30 secs, and annealing at 56.1 °C for 60 secs. We used as internal standard for RT-PCR (GAPDH) with a forward sequence: GTCTCCTGACTTCAA and reverse

sequence: ACCACCCTGTTGCTGTA. If both strands grew in a patient sample, this patient was classified as heterozygous. If only one strand grew in a patient sample, this patient was classified as homozygous. The thermal cycler software classifies each patient as homozygous wild type (CC), heterozygous (CT), and homozygous mutant (TT). Moreover, a negative control and control samples representing all genotypes were included in each reaction. Hardy Weinberg equilibrium was determined with a statistical test (Chi-squared). The variant of *AIPOQN* gene was in Hardy Weinberg equilibrium ($p = 0.53$).

BIOCHEMICAL DETERMINATIONS

Total cholesterol, HDL-cholesterol, triglycerides, C-reactive protein (CRP), fasting glucose and insulin were measured using an automated analyzer COBAS INTEGRA 400[®] (Roche Diagnostic, Montreal, Canada). LDL-cholesterol was determined using Friedewald's formula (LDL cholesterol = total cholesterol - HDL cholesterol - triglycerides / 5) (18). The homeostasis model assessment (HOMA-IR) was used to determine insulin resistance (glucose x insulin / 22.5) (19).

All adipokines were measured by enzyme immunoassay (ELISA); serum adiponectin levels (R&D systems, Inc., Minnesota, USA) with a normal range of 8.65-21.43 µg/ml (20), resistin levels (Biovendor Laboratory, Inc., Brno, Czech Republic) with a normal range of 4-12 ng/ml (21), and leptin levels (Diagnostic Systems Laboratories, Inc., Texas, USA) with a normal range of 10-100 ng/ml (22). The adiponectin/leptin ratio was calculated as a direct ratio between both values. Finally, CRP levels were determined by immunoturbimetry (Roche Diagnostics GmbH, Mannheim, Germany), with a normal range of (0-7 mg/dl).

ADIPOSIY PARAMETERS

In order to express body mass index (BMI), height and weight were measured with a stadiometer (Omrom, LA, CA, USA) and an electrical scale (Omrom, LA, CA, USA), respectively. BMI was calculated as body weight (kg) divided by height squared (m²). Waist circumference (WC) was determined with a flexible non-stretchable measuring tape (Omrom, LA, CA, USA) from the midpoint between the lateral iliac crest and the lowest rib to the nearest 0.5 cm. Impedanciometry was used to calculate total fat mass with an accuracy of 5 g (22) (EFG, Akern, It). Blood pressure was measured twice at 10-minute intervals using a digital sphygmomanometer (Omrom, LA, CA, USA).

STATISTICAL ANALYSIS

Sample size was determined to detect differences over 10 ng/dl of adiponectin after dietary intervention with 90 % power and 5 % significance. The sample size necessary was 175 obese patients in each diet group.

All analyses were performed under a dominant genetic model with rs822393 T-allele as the risk allele (CC vs. CT+TT). The Kolmogorov–Smirnov test was used to analyze variable distribution. A descriptive analysis of the data (mean, standard deviation, frequency of genotypes) and subsequently an inferential analysis (χ^2 test, Student's t-test, and non-parametric test) were carried out. A Bonferroni test was applied for multiple testing to reduce type-I error in association analysis. The statistical analysis to evaluate the interaction between the gene and each dietary intervention was performed using ANCOVA (covariance analysis) adjusted by age, sex, and BMI modeling the dependent variable with the starting values. IBM SPSS version 23.0 software package (SPSS Inc. Chicago, IL) was used to make the statistical analyses. Significance was assumed for $p < 0.05$.

RESULTS

Three hundred and sixty-one Caucasian obese patients were recruited in the study with the following genotypes (221 CC [61.2 %], 115 CT [31.9 %] and 25 TT [6.9 %]). Allelic frequency was C (0.77) and T (0.23). The mean age of the whole group was 51.1 ± 7.0 years (range: 27–61) and mean BMI was 36.9 ± 2.3 kg/m² (range: 31.5–38.3). Sex distribution was 259 females (71.7 %) and 102 males (28.3 %). Age was similar in both genotype groups (wild type [CC] vs. mutant type [CT+TT]) (51.9 ± 6.1 years vs 50.3 ± 6.1 years: ns). Sex distribution was similar in both genotype groups, males (27.3 % vs 29.2 %) and females (72.7 % vs 70.8 %).

All patients completed the 3-months follow-up period with both dietary interventions without dropouts (Fig. 1). Below we describe

the dietary intakes of the 176 obese patients (104 CC as wild genotype and 59 CT/13 TT as mutant genotype [CT+TT]) treated with diet P. In these patients, the basal evaluation of dietary intakes showed an energy of 2016.3 ± 318.8 kcal/day with the following macronutrient distribution: carbohydrate intake was 44.5 % of total calories (216.9 ± 51.1 g/day), fat intake was 35.3 % of total calories (79.1 ± 11.1 g/day) and protein intake was 20.1 % of calories 82.1 ± 13.1 g/day. During the 3 months of dietary intervention, these subjects followed the dietary recommendations of arm P: 1409.9 \pm 115.8 calories per day (45.3 % of carbohydrates, 34.2 % of lipids and 20.5 % of proteins). The percentages of dietary fats were: 20.2 % of saturated fats, 54.0 % of monounsaturated fats and 23.8 % of polyunsaturated fats (6.9 g per day of w-6 fatty acids, 1.8 g per day of w-3 fatty acids, and a w6/w3 ratio of 3.6). No differences were detected in physical activity between both genotype groups (164.1 ± 22.3 min/week vs 175.3 ± 30.9 min/week: $p = 0.39$).

In the 185 subjects (117 CC as wild genotype and 56 CT/12 TT as mutant genotype [CT+TT]) treated with diet M, basal energy intake was 2013.2 ± 292.9 kcal/day. The distributions of macronutrients in these subjects were: carbohydrate intake of 215.1 ± 29.1 g/day (44.0 % of calories), fat intake of 79.1 ± 14.3 g/day (34.6 % of calories) and protein intake of 86.2 ± 12.1 g/day (22.4 % of calories). During treatment, these patients reached the target recommendations of Diet M: 1401.1 \pm 102.3 calories per day (45.2 % of carbohydrates, 34.1 % of lipids and 20.7 % of proteins). The distribution of dietary fats was: 20.2 % of saturated fats, 68.3 % of monounsaturated fats and 11.5 % of polyunsaturated fats. Physical activity was similar in both genotype groups (175.1 ± 19.3 min/week vs 182.3 ± 23.1 min/week: $p = 0.48$).




Figure 1.

Flow chart with randomized and analyzed patients.

ADIPOSIITY PARAMETERS AND BLOOD PRESSURE

As showed in table I, there were no statistically significant differences in adiposity parameters and blood pressure levels either in the baseline values or in the values after the nutritional intervention. After both hypocaloric diets with two different profile of dietary fatty acids, body weight, body mass index (BMI), fat mass, waist circumference and systolic blood pressure decreased.

After the intervention with Diet P, patients of both genotypes (CC vs. CT+TT) responded with a similar improvement in body weight (-4.7 ± 1.1 kg vs. -4.6 ± 1.0 kg; $p = 0.41$), BMI (-1.6 ± 0.2 kg/m² vs. -1.4 ± 0.5 kg/m²; $p = 0.33$), fat mass (-3.4 ± 0.9 kg vs. -3.3 ± 0.8 kg; $p = 0.31$), waist circumference (-3.4 ± 0.9 cm vs. -3.1 ± 0.6 cm; $p = 0.52$) and systolic blood pressure (-13.0 ± 3.9 mmHg vs. -12.1 ± 2.9 mmHg; $p = 0.40$). After hypocaloric Diet M, both genotype groups (CC vs. CT+TT) had also similar improvements in body weight (-4.7 ± 1.2 kg vs. -4.8 ± 1.1 kg; $p = 0.43$), BMI (-1.6 ± 0.1 kg/m² vs. -1.3 ± 0.2 kg/m²; $p = 0.39$), fat mass (-3.8 ± 1.0 kg vs. -3.7 ± 0.7 kg; $p = 0.41$), waist circumference (-4.0 ± 1.1 cm vs. -3.9 ± 0.9 cm; $p = 0.41$) and systolic blood pressure (-11.1 ± 3.0 mmHg vs. -10.8 ± 2.7 mmHg; $p = 0.34$), too. These improvements previously mentioned were similar with both hypocaloric diets.

BIOCHEMICAL ASSAYS

For the variant rs822393 of the *ADIPOQ* gene there were no differences in basal biochemical parameters with a dominant model (CC vs CT+TT) (Table II), only the basal and posttreatment levels of HDL were lower in the T-allele carriers. Insulin, HOMA-IR, total cholesterol and LDL cholesterol significantly decreased in both genotype groups.

After dietary intervention with a polyunsaturated enriched hypocaloric diet (Diet P), subjects in both genotype groups showed a significant improvement in total cholesterol levels (CC vs CT+TT) (-20.1 ± 4.1 mg/dL vs. -20.2 ± 4.4 mg/dl; $p = 0.71$), LDL-cholesterol (-17.6 ± 3.1 mg/dl vs. -17.0 ± 2.9 mg/dL; $p = 0.43$), insulin levels (-5.4 ± 1.0 mU/L vs. -5.0 ± 0.4 mU/L; $p = 0.28$) and HOMA-IR (-1.7 ± 0.3 units vs. -1.4 ± 0.4 units; $p = 0.23$). A similar improvement in the same parameters and in the same magnitude was observed after the monounsaturated enriched hypocaloric diet (Diet M); total cholesterol levels (CC vs CT+TT) (-18.2 ± 5.2 mg/dL vs. -20.1 ± 4.4 mg/dl; $p = 0.32$), LDL-cholesterol (-16.9 ± 4.2 mg/dl vs. -16.3 ± 3.8 mg/dL; $p = 0.41$), insulin levels (-4.5 ± 1.1 mU/L vs. -4.6 ± 1.6 mU/L; $p = 0.32$) and HOMA-IR (-1.7 ± 0.1 units vs. -1.4 ± 0.2 units; $p = 0.39$). The magnitude of improvement of all these previously mentioned parameters was similar with both hypocaloric diets.

Moreover, HDL-cholesterol (CC vs CT+TT) (Δ : 5.6 ± 1.1 mg/dl vs. 2.7 ± 0.9 mg/dl; $p = 0.01$) improved only in non-T-allele carriers after Diet P. The same results were observed after Diet M (Δ : 5.5 ± 0.8 mg/dl vs. 3.1 ± 0.9 mg/dl; $p = 0.03$).

ADIPOKINES

Table III reports changes of serum adipokines and adiponectin/leptin ratio. Leptin levels were significantly improved after both dietary interventions and in both genotype groups. In both dietary intervention groups, basal and post-intervention adiponectin levels and adiponectin/leptin ratios were lower in T-allele carriers than in non-T-allele carriers.

After diet P and in non-T-allele carriers (CC vs. CT+TT), serum adiponectin (20.1 ± 2.9 ng/dl vs. 6.8 ± 3.0 ng/dl; $p = 0.02$) and adiponectin/leptin ratio (0.57 ± 0.1 units vs. 0.20 ± 0.08 units; $p = 0.03$) increased in a significant way. Similar results were observed after the intervention with Diet M. In non-T-allele carriers (CC vs. CT+TT), serum adiponectin (19.5 ± 2.9 ng/dl vs. 4.5 ± 2.8 ng/dl; $p = 0.01$) and adiponectin/leptin ratio (0.54 ± 0.1 units vs. 0.15 ± 0.08 units; $p = 0.03$) increased in a significant way.

DISCUSSION

In this interventional study of Caucasian obese subjects, we have shown a significant association between the rs822393 polymorphism of the *ADIPOQ* gene and metabolic response after two different hypocaloric diets, one enriched with monounsaturated fatty acids and the other enriched with polyunsaturated fatty acids. In these obese Caucasian subjects' study we reported a significant increase in HDL-cholesterol, adiponectin levels and adiponectin/leptin ratio in non-T-allele carriers, regardless of the type of diet. Finally, T-allele carriers showed lower levels of HDL-cholesterol, adiponectin and adiponectin/leptin ratio than non-T-allele carriers.

The rs822393 variant of the *ADIPOQ* gene has a scarce number of published studies with contradictory results. One of them is the *Healthy Lifestyle in Europe by Nutrition in Adolescents Study* (14). This cohort study of young people demonstrates a relationship between this genetic variant and HDL-cholesterol, as the results of our study of adult people. Surprisingly, these relationships with the lipid profile have not been found in other research studies (24). However, this rs822393 has been related in some studies with cardiovascular risk, hence its possible role in modifying the lipid profile (25). Probably the different ethnicities of the patients evaluated in the investigations can explain some of the differences found in the studies. For example, Rayma et al. had reported the same low HDL cholesterol levels in the T-allele carriers found by us in our sample of Caucasian obese patients, but in their case in obese Indian patients (26). The second metabolic finding in our study is low levels of adiponectin in T-allele carriers, too. This association has been previously reported in the CARDIA study (Coronary artery development in young adults) (27). These low levels of adiponectin could be explained by the fact that rs822393 is an intronic variant with the capacity to modify the alternative-splicing pattern (28). These two metabolic findings (low HDL-cholesterol and low adiponectin levels) are probably closely related, because adiponectin is capable of modulating the levels of HDL-cholesterol with activation of lipoprotein lipase and ATP-binding cassette transporter A1, and secondly with an increase in the hepatic production of ApoA1 (29-31).

Table I. Adiposity parameters and blood pressure at basal time and after both dietary interventions (mean ± SD)

Rs822393										
Characteristics	Diet P (n = 176)				Diet M (n = 185)				p	
	CC		CT+TT		CC		CT+TT		Time CC	
	Basal	3 months	Basal	3 months	Basal	3 months	Basal	3 months	Basal Genotype	Time CT+TT 3 months
BMI	37.2 ± 1.3	35.5 ± 1.1*	37.0 ± 1.0	35.6 ± 1.2*	37.3 ± 1.1	35.7 ± 1.2*	37.1 ± 1.2	35.8 ± 2.1*	p = 0.01	p = 0.01
									p = 0.41	p = 0.41
									p = 0.02	p = 0.02
									p = 0.52	p = 0.52
Weight (kg)	98.7 ± 2.1	94.0 ± 2.0*	97.2 ± 3.0	92.5 ± 2.0*	98.1 ± 3.2	93.4 ± 2.1*	97.6 ± 2.1	92.9 ± 3.0*	p = 0.01	p = 0.01
									p = 0.54	p = 0.54
									p = 0.02	p = 0.02
									p = 0.53	p = 0.53
Fat mass (kg)	41.3 ± 0.3	37.9 ± 0.5*	40.1 ± 0.2	36.7 ± 0.6*	40.3 ± 1.1	36.3 ± 0.9*	40.0 ± 1.1	36.1 ± 1.2*	p = 0.01	p = 0.01
									p = 0.51	p = 0.51
									p = 0.02	p = 0.02
									p = 0.42	p = 0.42
WC (cm)	114.1 ± 5.1	110.7 ± 3.3*	112.4 ± 3.1	109.3 ± 2.1*	114.4 ± 3.1	110.1 ± 2.1*	114.2 ± 1.0	109.9 ± 1.2*	p = 0.01	p = 0.01
									p = 0.49	p = 0.49
									p = 0.01	p = 0.01
									p = 0.53	p = 0.53
SBP (mmHg)	140.1 ± 3.2	125.8 ± 3.2*	139.1 ± 2.0	124.1 ± 1.1*	138.3 ± 4.1	127.1 ± 4.0*	137.9 ± 3.1	127.1 ± 2.9*	p = 0.01	p = 0.01
									p = 0.38	p = 0.38
									p = 0.01	p = 0.01
									p = 0.52	p = 0.52
DBP (mmHg)	80.4 ± 3.1	79.3 ± 3.0	80.2 ± 2.0	78.9 ± 2.1	80.1 ± 2.0	79.4 ± 3.1	80.2 ± 2.1	80.1 ± 2.5	p = 0.41	p = 0.41
									p = 0.50	p = 0.50
									p = 0.42	p = 0.42
									p = 0.49	p = 0.49

BMI: body mass index; DBP: diastolic blood pressure; SBP: systolic blood pressure; WC: waist circumference. Statistical differences in each genotype group: *No statistical differences between genotype groups.

Table II. Biochemical parameters at basal time and after both dietary interventions (mean ± SD)

Characteristics	Rs822393											
	Diet P (n = 176)				Diet M (n = 185)				p			
	CC		CT+TT		CC		CT+TT		Time CC		Time CC	
	Basal	3 months	Basal	3 months	Basal	3 months	Basal	3 months	Basal Genotype	Time CT+TT	Basal Genotype	Time CT+TT
Glucose (mg/dl)	101.9 ± 4.2	100.2 ± 3.1	99.7 ± 3.0	98.9 ± 2.1	101.0 ± 4.1	98.3 ± 3.3	101.9 ± 4.2	99.1 ± 3.2	p = 0.22	101.0 ± 4.1	p = 0.31	99.1 ± 3.2
									p = 0.38		p = 0.40	
									p = 0.14		p = 0.33	
									p = 0.39		p = 0.32	
Total cholesterol (mg/dl)	218.3 ± 7.1	198.4 ± 4.2*	209.2 ± 6.1	189.9 ± 5.2*	217.3 ± 5.0	199.1 ± 2.0*	205.9 ± 3.9	185.8 ± 3.1*	p = 0.04	217.3 ± 5.0	p = 0.01	185.8 ± 3.1*
									p = 0.36		p = 0.16	
									p = 0.03		p = 0.02	
									p = 0.45		p = 0.33	
LDL-cholesterol (mg/dl)	128.3 ± 3.3	111.9 ± 4.1*	129.1 ± 4.1	112.1 ± 3.2*	130.1 ± 3.0	113.2 ± 3.1*	129.8 ± 4.1	113.4 ± 3.1*	p = 0.03	130.1 ± 3.0	p = 0.02	113.4 ± 3.1*
									p = 0.37		p = 0.26	
									p = 0.02		p = 0.03	
									p = 0.45		p = 0.43	
HDL-cholesterol (mg/dl)	50.3 ± 2.0	55.9 ± 1.1*	45.1 ± 3.1†	47.6 ± 2.6†	51.4 ± 2.2	57.0 ± 1.9*	45.8 ± 2.0†	48.9 ± 3.1†	p = 0.01	51.4 ± 2.2	p = 0.04	48.9 ± 3.1†
									p = 0.02		p = 0.41	
									p = 0.11		p = 0.39	
									p = 0.03		p = 0.48	
Triglycerides (mg/dl)	121.9 ± 10.1	120.4 ± 9.2	121.9 ± 11.2	120.5 ± 8.2	121.1 ± 8.1	120.8 ± 8.2	119.1 ± 7.9	118.2 ± 8.1	p = 0.52	121.1 ± 8.1	p = 0.60	118.2 ± 8.1
									p = 0.48		p = 0.82	
									p = 0.56		p = 0.54	
									p = 0.41		p = 0.29	
CRP (ng/dl)	4.3 ± 2.0	4.4 ± 1.9	4.9 ± 1.1	4.2 ± 1.2	4.2 ± 1.1	4.3 ± 1.0	4.5 ± 1.0	4.4 ± 1.1	p = 0.41	4.2 ± 1.1	p = 0.58	4.4 ± 1.1
									p = 0.50		p = 0.79	
									p = 0.49		p = 0.56	
									p = 0.15		p = 0.39	
Insulin (mIU/L)	15.7 ± 2.1	10.1 ± 1.9*	15.0 ± 1.9	10.1 ± 1.2*	15.4 ± 2.0	10.9 ± 1.2*	14.9 ± 2.0	9.9 ± 2.1*	p = 0.01	15.4 ± 2.0	p = 0.01	9.9 ± 2.1*
									p = 0.36		p = 0.32	
									p = 0.02		p = 0.02	
									p = 0.43		p = 0.34	
HOMA-IR	4.2 ± 0.3	2.5 ± 0.9*	4.1 ± 0.5	2.3 ± 0.4*	4.1 ± 0.7	2.4 ± 0.8*	4.0 ± 0.6	2.1 ± 0.8*	p = 0.02	4.1 ± 0.7	p = 0.02	2.1 ± 0.8*
									p = 0.31		p = 0.36	
									p = 0.01		p = 0.03	
									p = 0.43		p = 0.54	

CRP: C-reactive protein; HOMA-IR: homeostasis model assessment. Statistical differences in each genotype group: *Statistical differences between genotype groups; †.

Table III. Adipokines and cytokine levels (mean \pm SD)

Rs822393														
Characteristics	Diet P (n = 176)				p Time CC Basal Genotype Time CT+TT 3 months			Diet M (n = 185)			p Time CC Basal Genotype Time CT+TT 3 months			
	CC		CT+TT		Basal	3 months	p	CC		CT+TT		Basal	3 months	p
	Basal	3 months	Basal	3 months				Basal	3 months	Basal	3 months			
Resistin (ng/dl)	6.6 \pm 1.1	6.8 \pm 2.2	5.1 \pm 2.1	5.4 \pm 2.0	5.1 \pm 1.3	5.4 \pm 1.4	5.1 \pm 1.1	4.9 \pm 1.0	p = 0.51	p = 0.61	p = 0.72	p = 0.71	p = 0.45	p = 0.24
Adiponectin (ng/dl)	19.1 \pm 4.1	39.1 \pm 4.9*	10.1 \pm 3.1 [†]	16.9 \pm 6.1 [†]	15.9 \pm 1.2	35.4 \pm 2.2*	11.2 \pm 2.9 [†]	15.7 \pm 1.3 [†]	p = 0.01	p = 0.02	p = 0.02	p = 0.43	p = 0.39	p = 0.24
Leptin (ng/dl)	70.9 \pm 12.3	45.1 \pm 9.5*	75.5 \pm 9.1	50.1 \pm 9.1*	71.3 \pm 9.1	46.2 \pm 8.1*	78.3 \pm 7.2	53.4 \pm 4.1*	p = 0.01	p = 0.01	p = 0.22	p = 0.29	p = 0.02	p = 0.43
Ratio adiponectin/ leptin (ng/dl)	0.29 \pm 0.09	0.86 \pm 0.1*	0.13 \pm 0.1 [†]	0.33 \pm 0.2 [†]	0.22 \pm 0.08	0.76 \pm 0.1*	0.14 \pm 0.07 [†]	0.29 \pm 0.1 [†]	p = 0.01	p = 0.01	p = 0.02	p = 0.02	p = 0.24	p = 0.03

Statistical differences (p < 0.05) in each genotype group: *Statistical differences between genotype groups; [†].

A previous study of 3 months with a caloric intake of 1500 calories/day and a Mediterranean diet profile with 50 % of all fats in the form of monounsaturated fats, also demonstrated a significant improvement in adiponectin levels, adiponectin/leptin ratio and HDL-cholesterol (32). In a second intervention study, the same metabolic results were observed (33). In this case, the diet was 1000 calories a day and the intervention lasted 9 months, with a higher percentage of monounsaturated fats, reaching 60 % of the total fat provided. Some studies have demonstrated higher levels of adiponectin after diets enriched in unsaturated fat than in diets enriched in protein or carbohydrates (34). In one study, mean adiponectin levels showed a significant increase after supplementation with omega-3 fatty acids for 3 months (35). In a rat model, a lower proportion of dietary saturated/monounsaturated/polyunsaturated fatty acids modified the expression of adiponectin with a high-fat diet (36). Even in non-obese individuals, a differential response for postprandial adiponectin has been demonstrated as a function of the amount of sugar and fat in a typical meal (37). Finally, in the GOLDN study, a significant association was reported between a genetic variant of the *ADIPOQ* gene and obesity and metabolic-related traits with dietary modifications (38).

The strength of our study was in its design a randomized, controlled, feeding trial with high retention and adherence and diets with a practical relevance to the population. Limitations included a small sample size, and small changes in HDL cholesterol and adiponectin levels. Second limitation is that we only determined one SNP of *ADIPOQ*, other SNPs could be related to our findings. Third, the associations between *ADIPOQ* variant and metabolic changes could be modified by other gene-environmental interactions, that we have not been able to consider in our design. Fourth, the findings are in metabolic alterations and not in cardiovascular events, but the existence of a relationship with the adiponectin/leptin ratio is promising. For example, an adiponectin/leptin ratio below or near to 0.5 may indicate an increase in metabolic risk (39,40), as shown by carriers of the T-allele before and after dietary intervention. Finally, the self-reported dietary intake is not reliable and it might include bias of under- or over-reporting.

In conclusion, after two different hypocaloric diets, enriched in polyunsaturated fatty acids and monounsaturated fatty acids, obese subjects with the T-allele of rs822393 did not improve adiponectin levels, adiponectin/leptin ratio, and HDL-cholesterol, despite the loss of weight. Therefore, the genotyping of patients with this rs822393 variant before starting a hypocaloric diet enriched in fat is interesting to predict their metabolic response, which is more important than the fat profile of the diet.

AUTHOR CONTRIBUTIONS

Daniel de Luis designed the study, performed the statistical analysis and wrote the article. He contributed to the analysis of data for the work and revised it critically for important intellectual content. He approved the version to be published and is ac-

countable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Olatz Izaola performed the anthropometric evaluation and control of dietary intake. She contributed to the acquisition of data for the work and revised it critically for important intellectual content. She approved the version to be published and is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Juan José López performed the anthropometric evaluation and statistical analysis. He contributed to the acquisition of data for the work and revised it critically for important intellectual content. He approved the version to be published and is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Rocío Aller performed the biochemical evaluation, including genotypes, and wrote the article. She contributed to the analysis of data for the work and revised it critically for important intellectual content. She approved the version to be published and is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

REFERENCES

1. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. *Lancet* 2011;377:557-67. DOI: 10.1016/S0140-6736(10)62037-5
2. Riserus U, Willett WC, Hu FB. Dietary fats and prevention of type 2 diabetes. *Prog Lipid Res* 2009;48:44-51. DOI: 10.1016/j.plipres.2008.10.002
3. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. *Nat Med* 2002;8(11):1288-95. DOI: 10.1038/nm788
4. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. *Nat Med* 2001;7(8):941-6. DOI: 10.1038/90984
5. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. *Biochem Biophys Res Commun* 1999;257(1):79-83. DOI: 10.1006/bbrc.1999.0255
6. Duncan BB, Schmidt MI, Pankow JS, Bang H, Couper D, Ballantyne CM, et al. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. *Diabetes* 2004;53(9):2473-8. DOI: 10.2337/diabetes.53.9.2473
7. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, et al. Adiponectin as a biomarker of the metabolic syndrome. *Circ J* 2004;68(11):975-81. DOI: 10.1253/circj.68.975
8. de Luis DA, Aller R, Izaola O, Bachiller R. Role of rs6923761 gene variant in glucagon-like peptide 1 receptor in basal GLP-1 levels, cardiovascular risk factor and serum adipokine levels in naïve type 2 diabetic patients. *J Endocrinol Invest* 2015;38:143-7. DOI: 10.1007/s40618-014-0161-y
9. Yang WS, Chuang LM. Human genetics of adiponectin in the metabolic syndrome. *J Mol Med* 2006;84:112-21. DOI: 10.1007/s00109-005-0011-7
10. Takahashi M, Arita Y, Yamagata K, Matsukawa Y, Okutomi K, Horie M, et al. Genomic structure and mutations in adipose-specific gene, adiponectin. *Int J Obes Relat Metab Disord* 2000;24:861-8. DOI: 10.1038/sj.ijo.0801244
11. Comuzzie AG, Funahashi T, Sonnenberg G. The genetic basis of plasma variation in adiponectin, a global endophenotype for obesity and the metabolic syndrome. *J Clin Endocrinol Metab* 2001;86:4321-5. DOI: 10.1210/jcem.86.9.7878

12. de Luis DA, Primo D, Izaola O, Gómez E, Bachiller R. Serum Lipid and Adiponectin Improvements after a Mediterranean Dietary Pattern in Non-G-Allele Carriers of the Variant rs3774261. *Lifestyle Genom* 2020;13:164-71. DOI: 10.1159/000508819
13. Rasmussen-Torvik LJ, Pankow JS, Jacobs Jr DR, Steinberger J, Moran A, Sinaiko AR. The association of SNPs in ADIPOQ, ADIPOR1, and ADIPOR2 with insulin sensitivity in a cohort of adolescents and their parents. *Hum Genet* 2009;125:21-8. DOI: 10.1007/s00439-008-0595-4
14. Salazar-Tortosa DF, Pascual-Gamarra JM, Labayen I, Rupérez AI, Censi L, Béghin L, et al. Single nucleotide polymorphisms of ADIPOQ gene associated with cardiovascular disease risk factors in European adolescents: the Healthy Lifestyle in Europe by Nutrition in Adolescence study. *J Hypertens* 2020;38:1971-9. DOI: 10.1097/HJH.0000000000002502
15. Primo D, Izaola O, de Luis D. Serum lipid and adiponectin/leptin ratio changes after a Mediterranean dietary pattern in non-g-allele carriers of the genetic variant of adiponectin gene rs822393. *Eur Rev Med Pharmacol Sci* 2021;25:3489-98. DOI: 10.26355/eurrev_202105_25831
16. AlSaleh A, O'Dell SD, Frost GS, Griffin BA, Lovegrove JA, Jebb SA, et al. Single nucleotide polymorphisms at the ADIPOQ gene locus interact with age and dietary intake of fat to determine serum adiponectin in subjects at risk of the metabolic syndrome. *Am J Clin Nutr* 2011;94:262-9. DOI: 10.3945/ajcn.111.014209
17. Mataix J, Mañas M. Tablas de composición de alimentos españoles. Ed: University of Granada; 2003.
18. Friedewald WT, Levy RJ, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. *Clin Chem* 1972;18:499-502.
19. Mathews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985;28:412-4. DOI: 10.1007/BF00280883
20. Meier U, Gressner M. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, Ghrelin, adiponectin, and resistin. *Clinical Chemistry* 2004;50:1511-25. DOI: 10.1373/clinchem.2004.032482
21. Pfutzner A, Langefeld M, Kunt T. Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. *Clin Lab* 2003;49:571-6.
22. Suominen P. Evaluation of an enzyme immunometric assay to measure serum adiponectin concentrations. *Clin Chem* 2004;50:219-21. DOI: 10.1373/clinchem.2003.025833
23. Lukaski H, Johnson PE. Assessment of fat-free mass using bioelectrical impedance measurements of the human body. *Am J Clin Nutr* 1985;41:810-7. DOI: 10.1093/ajcn/41.4.810
24. Won HH, Natarajan P, Dobbyn A, Jordan DM, Roussos P, Lage K, et al. Disproportionate Contributions of Select Genomic Compartments and Cell Types to Genetic Risk for Coronary Artery Disease. *PLoS Genet*. 2015;11:e1005622. DOI: 10.1371/journal.pgen.1005622
25. Christou GA, Kiortsis DN. Adiponectin and lipoprotein metabolism. *Obes Rev* 2013;14:939-49. DOI: 10.1111/obr.12064
26. Wassel CL, Pankow JS, Jacobs DR Jr, Steffes MW, Li N, Schreiner PJ. Variants in the adiponectin gene and serum adiponectin: the Coronary Artery Development in Young Adults (CARDIA) Study. *Obesity (Silver Spring)* 2010;18:2333233-8. DOI: 10.1038/oby.2010.85
27. Ramya K, Ayyappa KA, Ghosh S, Mohan V, Radha V. Genetic association of ADIPOQ gene variants with type 2 diabetes, obesity and serum adiponectin levels in south Indian population. *Gene* 2013;532:253-62. DOI: 10.1016/j.gene.2013.09.012
28. Jacob AG, Smith CWJ. Intron retention as a component of regulated gene expression programs. *Hum Genet* 2017;136:1043-57. DOI: 10.1007/s00439-017-1791-x
29. Emerging Risk Factors Collaboration, Danesh J, Erqou S, Walker M, Thompson SG, Tipping R, et al. The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. *Eur J Epidemiol* 2007;22(12):839-69. DOI: 10.1007/s10654-007-9165-7
30. Yanai H, Yoshida H. Beneficial Effects of Adiponectin on Glucose and Lipid Metabolism and Atherosclerotic Progression: Mechanisms and Perspectives. *Int J Mol Sci* 2019;20:1190. DOI: 10.3390/ijms20051190
31. Jacob AG, Smith CWJ. Intron retention as a component of regulated gene expression programs. *Hum Genet* 2017;136:1043-57. DOI: 10.1007/s00439-017-1791-x
32. Primo D, Izaola O, de Luis D. Serum lipid and adiponectin/leptin ratio changes after a Mediterranean dietary pattern in non-g-allele carriers of the genetic variant of adiponectin gene rs822393. *Eur Rev Med Pharmacol Sci* 2021;25:3489-98. DOI: 10.26355/eurrev_202105_25831
33. Izaola O, Primo D, de Luis D. Dietary Intervention during 9 Months with a Hypocaloric Diet, Interaction of the Genetic Variant of Adiponectin Gene rs822393 with Metabolic Parameters. *Dis Markers* 2022;2022:7058389. DOI: 10.1155/2022/7058389
34. Kasim-Karakas SE, Tsodikov A, Singh U, Jialal I. Responses of inflammatory markers to a low-fat, high-carbohydrate diet: effects of energy intake. *Am J Clin Nutr* 2006;83:774-9. DOI: 10.1093/ajcn/83.4.774
35. Mejia-Montilla J, Reyna-Villasmil E, Domínguez-Brito L, Naranjo-Rodríguez C, Noriega-Verdugo D, Padilla-Samaniego M, Vargas-Olalla V. Supplementation with omega-3 fatty acids and plasma adiponectin in women with polycystic ovary syndrome. *Endocrinol Diabetes Nutr (Engl Ed)* 2018;65:192-9. DOI: 10.1016/j.endinu.2017.12.010
36. Yang X, Zhang Y, Lin J, Pen A, Ying C, Cao W, et al. A lower proportion of dietary saturated/monounsaturated/polyunsaturated fatty acids reduces the expression of adiponectin in rats fed a high-fat diet. *Nutr Res* 2012;32:285-91. DOI: 10.1016/j.nutres.2011.12.016
37. Larsen MA, Isaksen VT, Paulssen EJ, Goll R, Florholmen JR. Postprandial leptin and adiponectin in response to sugar and fat in obese and normal weight individuals. *Endocrine* 2019;66:517-25. DOI: 10.1007/s12020-019-02102-9
38. Warodomwicht D, Shen J, Arnett DK, Tsai MY, Kabagambe EK, Peacock JM, et al. ADIPOQ polymorphisms, monounsaturated fatty acids, and obesity risk: the GOLDN study. *Obesity (Silver Spring)* 2009;17:510-7. DOI: 10.1038/oby.2008.583
39. Frühbeck G, Catalán V, Rodríguez A, Ramírez B, Becerril S, Salvador J, et al. Adiponectin-leptin Ratio is a Functional Biomarker of Adipose Tissue Inflammation. *Nutrients* 2019;11:454. DOI: 10.3390/nu11020454
40. Frühbeck G, Catalán V, Rodríguez A, Gómez-Ambrosi J. Adiponectin-leptin ratio: A promising index to estimate adipose tissue dysfunction. Relation with obesity-associated cardiometabolic risk. *Adipocyte* 2018;7:57-62. DOI: 10.1080/21623945.2017.1402151